Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer and other therapeutic areas. The company's pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system.

Pierre Belichard

Stanislav Dusko EHRLICH

Enterome

Biotech 365 provides business support services for biotech companies, focusing on fundraising, licensing, and connecting companies with healthcare investors through their global network.

Biotech 365

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

DBV Technologies S.A.

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Metric
Company Name	Enterome	Biotech 365	DBV Technologies S.A.	Neovacs S.A.
Symbol			DBV	ALNEV
MSH ID	COM:ENTEROME	COM:BIOTECH-365	COM:DBV-TECHNOLOGIES	COM:NEOVACS
Market	PRIVATE	PRIVATE	STOCKS	STOCKS
Sector	Healthcare & Health Services	Financial Services & Finance	Healthcare	Healthcare
Industry	Biopharmaceuticals	Biotechnology Business Services	Biotechnology	Biotechnology
Country		FR	FR	FR
Stage				Post-IPO Debt
Employee Count	51		105	22
Website	enterome.com	biotech-365.com	dbv-technologies.com	neovacs.com
LinkedIn			dbv-technologies	neovacs
Founders

Metric
Market Cap		77.97M	52.99K
Enterprise Value
Monthly Web Traffic	68
Web Traffic Growth	-0.57
Valuation
Raised Capital			4.77M

Metric
Revenue				563.41K
Revenue (LTM)
Revenue (NTM)
Gross Profit				-7.13M
EBITDA				-7.12M
Operating Income				-7.30M
Net Income				-9.24M
EPS				-0.00
Diluted EPS				-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				-9.71
Operating Profit Margin				-12.95
EBITDA Margin				-12.64
Net Profit Margin				-16.39
Return on Equity				-0.12
Return on Assets				-0.11
Return on Capital Employed				-0.14

ENTE

COM:ENTEROME

Enterome

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				5.78
EV Multiple				-0.04

Metric
Days Sales Outstanding
Days Payables Outstanding				1.22K
Days Inventory Outstanding
Operating Cycle				11.67K
Cash Conversion Cycle				11.39K
Asset Turnover				0.01

Metric
Operating Cash Flow				-2.02M
Free Cash Flow				-2.24M
Cash Flow to Debt				-1.47
Operating Cash Flow/Sales				-3.59
Free Cash Flow Yield				-0.00

Metric
Cash & Equivalents				936.97K
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization				0.06
Debt to Assets				0.02
Current Ratio				2.32
Quick Ratio				1.34

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue